← Back to Home

One Pancreatic Tumor, Multiple Evolutionary Paths: Single-Cell Study Traces MYC’s Role

Analyzing more than 440,000 cells, researchers found that different cell populations within pancreatic cancer can evolve along their own paths. Reducing MYC expression shifted aggressive cells toward a less aggressive state in experimental models, but whether this can improve treatment outcomes for patients remains to be verified.

By SURL BioNews

Part of the difficulty in treating pancreatic cancer lies within a single tumor: cancer cells are not a uniform population. They may change and adapt independently, leaving different routes to survival. A new study examined tumors at single-cell resolution to trace how these differences relate to aggressiveness, the immune environment, and changes following treatment, while also identifying clues to possible ways of altering cell states.

The study, a collaboration involving New York University, the University of California San Diego, and other institutions, was published in *Nature Genetics* on October 13, 2026. The team analyzed 443,451 cells from 62 pancreatic ductal adenocarcinoma tumor samples and incorporated spatial transcriptomic data for 11 of the tumors, linking gene activity to locations within the tissue. Another 6 patients provided paired samples collected before and after chemotherapy, allowing researchers to compare changes in cell populations following treatment.

The analysis showed that individual tumors could contain 2 to 11 genetically distinct cancer cell clones—groups of cells with similar genetic makeup. Within these clones, the proportions of less aggressive “classical” cells and more aggressive “basal” cells varied. Analyzing tumors in bulk can obscure this mixture; identifying cells individually reveals how different clones evolve in parallel and how their interactions with surrounding immune and stromal cells differ.

One line of evidence pointed to MYC. By integrating the evolutionary relationships among clones with changes in gene copy number, the researchers found that amplification of the chromosome 8q24 region containing MYC was repeatedly associated with a shift from the classical to the basal state, accompanied by weakening of gene programs related to immune responses. This gives more concrete meaning to the idea of a tumor “rewriting its DNA”: the study traced gains and losses of gene segments and their relationship to cell states, rather than cancer cells purposefully choosing how to evade treatment.

The team then reduced MYC expression in mouse and human primary experimental models and found that classical transcriptional features were reactivated, while pathways related to immune responses also showed some recovery. This functional experiment supports a role for MYC in maintaining a basal state with weaker immune responses. However, changes in cellular features cannot be directly equated with tumor shrinkage in patients or taken as proof that existing treatments can thereby become effective again.

Location within the tumor also matters. Spatial analysis found that clones with a dispersed distribution had stronger features of epithelial–mesenchymal transition and immune suppression and were associated with metastatic potential and colonization of lymph nodes. These findings connect genetic differences in cancer cells to their surrounding tissue environment, suggesting that understanding disease progression also requires knowing which cell populations occur where.

This study offers a direction for intervening in tumor evolution but has not established a new clinical treatment. In particular, the paired data from before and after chemotherapy came from only 6 patients, and most evolutionary relationships still had to be reconstructed from molecular data. The next steps are to determine which patients’ tumors depend most on MYC, how long the altered state can persist after intervention, and whether this change can safely translate into better treatment responses.

References

  1. ScienceDaily Top Health
  2. NYU Langone Health
  3. University of California San Diego